Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Novavax, Inc.    NVAX

NOVAVAX, INC.

(NVAX)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

NOVAVAX INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/19/2019 | 04:22pm EDT

Item 2.02. Results of Operations and Financial Condition.

Fourth Quarter Financial Results

On March 18, 2019, Novavax, Inc. (the "Company") issued a press release announcing the Company's financial results for the quarter ended December 31, 2018. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Items 2.02 and 9.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.




(d)    Exhibits.



Exhibit No.                                 Description

  99.1          Press release, dated March 18, 2019, regarding the Company's
              financial results for the quarter ended December 31, 2018.

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVAVAX, INC.
03/19NOVAVAX INC : Results of Operations and Financial Condition, Financial Statement..
AQ
03/18NOVAVAX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
03/18NOVAVAX : 4Q Earnings Snapshot
AQ
03/18Novavax Reports Fourth Quarter and Year-End 2018 Financial Results
GL
03/11Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 F..
GL
03/02NOVAVAX : RSV vaccine ResVax fails in Phase III trial
AQ
03/01NOVAVAX : Announces Topline Results from Phase 3 PrepareTM Trial of ResVax for P..
AQ
02/28NOVAVAX INC : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
AQ
02/28Novavax Announces Topline Results from Phase 3 PrepareTM Trial of ResVax&trad..
GL
01/05NOVAVAX : shares surge following positive Phase 2 trial of flu vaccine
AQ
More news
Financials ($)
Sales 2019 9,50 M
EBIT 2019 -165 M
Net income 2019 -183 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 22,2x
EV / Sales 2020 43,7x
Capitalization 211 M
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 1,81 $
Spread / Average Target 228%
EPS Revisions
Managers
NameTitle
Stanley C. Erck President, Chief Executive Officer & Director
James F. Young Chairman
Timothy Jon Hahn Senior VP-Global Manufacturing Operations
John J. Trizzino CFO, Treasurer, Chief Business Officer & Senior VP
Louis F. Fries Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVAVAX, INC.-70.01%211
IQVIA HOLDINGS INC24.34%28 572
CELLTRION, INC.--.--%22 987
LONZA GROUP17.24%22 239
INCYTE CORPORATION34.72%18 338
SEATTLE GENETICS, INC.28.59%11 698